Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy
Publication Date: November 29, 2018
Key Points
Key Points
Women with node-positive breast cancer should receive extended therapy including an aromatase inhibitor (AI) for up to a total of 10 years of adjuvant endocrine treatment.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Treatment
Treatmen...
...dated Recommendations on Extended Therapy...
...women with node-negative breast cancer are...
...de-positive breast cancer should be off...
...receiving extended adjuvant endocrine...
...revention of secondary or contralateral breast ca...
...therapy carries ongoing risks and si...
...ations on Ovarian Suppression...
...nel recommends that higher risk patients should r...
...with Stage II or Stage III breast cancers who woul...
Women with Stage I or II breast cancers at highe...
...e I breast cancers not warranting chemotherapy sho...
...node-negative cancers 1 centimeter or le...
...ssion may be administered with either tamoxife...
...Recommended Pharmaceuticals for HR+ Breast Can...
...2. Prognostic Factors for Recurre...